Health
SACRAMENTO – Assemblymember Mariko Yamada (D–Davis), chair of the Assembly Committee on Aging & Long-Term Care, has introduced the Home Care Services Act of 2013.
AB 322, co-authored by Senator Lou Correa (D–Santa Ana), establishes regulations for private home care agencies.
“California is aging, and is already home to the largest population of dependent adults in the nation,” Yamada said. “There should be clear standards for training and background checks for agency-based caregivers who wish to serve this vulnerable population.”
AB 322 authorizes the California Department of Social Services to license and regulate private home care agencies that hire and match home care aides with clients that need nonmedical assistance to live at home independently.
Many seniors and persons with disabilities, or their families, choose private home care agencies to secure the services of a comprehensively screened professional caregiver and avoid the liabilities and tax consequences of being an employer of an independent caregiver.
Currently, the only requirement to establish a homecare agency in California is a business license.
The lack of oversight and regulation of private homecare agencies can leave consumers without safeguards to protect them from negligent or criminal conduct.
The Home Care Services Act of 2013 responds to an industry call for regulation.
Assemblymember Yamada represents the Fourth Assembly District which includes all or parts of Colusa, Lake, Napa, Solano, Sonoma and Yolo counties.
- Details
- Written by: Editor
The Muscular Dystrophy Association has awarded a $400,000 infrastructure grant to National Institutes of Health (NIH) researchers to support exome sequencing on samples taken from 1,000 people with amyotrophic lateral sclerosis (ALS).
Data generated by the project will be made publicly available online and is expected to accelerate the pace of ALS research by helping scientists identify genes associated with the disease.
The MDA funding will enhance research conducted by the National Institute on Aging (NIA, part of the NIH) to better understand the genetic basis of neuromuscular disorders. The project will be led by Bryan Traynor, Ph.D., of the NIA Intramural Research Program in Bethesda, Md.
“It’s exciting to fund such an important project that will significantly expand the existing resources available for scientists to use in their ongoing efforts to better understand ALS,” said MDA Vice President of Research Jane Larkindale. “MDA is pleased to be able to collaborate with the NIH on this unique, first-of-its-kind endeavor.”
Exome-sequencing technology decodes stretches of DNA called exons, which contain instructions used in protein synthesis. Although exons make up only about 1.5 percent of the genome, the vast majority of disease-causing mutations occur in these sections. Exome data can be used to identify genes associated with human diseases.
“The whole team is tremendously excited about this project, which will establish a unique resource for the ALS research community aimed at accelerating gene discovery for this devastating disease,” said Traynor, who heads the Neuromuscular Disease Research Unit in the NIA’s Laboratory of Neuroscience. “Understanding the genetics underlying ALS is essential to understanding its onset and progression and in ultimately developing therapies to help patients.”
The exome-sequencing project is expected to be completed within 12 months. In that time, it will produce exome data from post-mortem tissue samples for 360 people with the sporadic form of ALS who have donated tissues to the NIH and for 640 additional tissue samples from sporadic ALS patients who have donated tissues to the Coriell ALS Repository.
Exome-sequencing data from a large number of people unaffected by ALS will be used for comparison in analysis.
MDA’s $400,000 infrastructure grant to support the project was made through the Association’s translational research program. To learn more, read the MDA/ALS Newsmagazine article “Unique ALS ‘Exome-Sequencing’ Project Is Focus of New Grant.”
Amyotrophic lateral sclerosis (also known as Lou Gehrig’s disease) attacks the nerve cells that control muscles, ultimately resulting in paralysis of all voluntary muscles, including those used for breathing.
Only about 5 percent of ALS is familial (where there is a history of ALS in more than one family member) with the other 95 percent occurring sporadically (without any family history of the disease). Average life expectancy for people with the disease is three to five years after diagnosis.
- Details
- Written by: Editor
How to resolve AdBlock issue?